Andra AP fonden grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 25.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,500 shares of the medical instruments supplier’s stock after acquiring an additional 2,500 shares during the quarter. Andra AP fonden’s holdings in Becton Dickinson and were worth $3,162,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Stifel Financial Corp boosted its position in shares of Becton Dickinson and by 3.1% in the third quarter. Stifel Financial Corp now owns 775,989 shares of the medical instruments supplier’s stock valued at $197,614,000 after acquiring an additional 23,196 shares during the period. JT Stratford LLC boosted its position in shares of Becton Dickinson and by 7.6% in the third quarter. JT Stratford LLC now owns 932 shares of the medical instruments supplier’s stock valued at $236,000 after acquiring an additional 66 shares during the period. Virtu Financial LLC bought a new stake in shares of Becton Dickinson and in the third quarter valued at approximately $364,000. Vestor Capital LLC boosted its position in shares of Becton Dickinson and by 2.9% in the third quarter. Vestor Capital LLC now owns 62,156 shares of the medical instruments supplier’s stock valued at $15,723,000 after acquiring an additional 1,761 shares during the period. Finally, Endurant Capital Management LP acquired a new position in shares of Becton Dickinson and in the third quarter valued at $5,581,000. 84.65% of the stock is owned by institutional investors.
Shares of NYSE BDX opened at $259.03 on Tuesday. The business has a fifty day simple moving average of $251.87 and a 200 day simple moving average of $249.02. The company has a current ratio of 1.18, a quick ratio of 0.72 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $69.91 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 1.82 and a beta of 1.07. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $264.74.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.22%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date is Monday, December 9th. Becton Dickinson and’s dividend payout ratio is presently 26.37%.
In other Becton Dickinson and news, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the transaction, the senior vice president now directly owns 5,180 shares in the company, valued at $1,347,214.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the transaction, the chief executive officer now owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders have sold 22,345 shares of company stock valued at $5,847,029 over the last quarter. Corporate insiders own 0.12% of the company’s stock.
BDX has been the subject of a number of recent research reports. KeyCorp cut their target price on Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Piper Jaffray Companies cut their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Wells Fargo & Co upped their target price on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $266.00.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Do stock splits help investors?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.